Repligen Financial Statements From 2010 to 2026
| RGN Stock | EUR 141.40 1.35 0.95% |
Check Repligen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Repligen's main balance sheet or income statement drivers, such as , as well as many indicators such as . Repligen financial statements analysis is a perfect complement when working with Repligen Valuation or Volatility modules.
Repligen |
Repligen Company Return On Equity Analysis
Repligen's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Repligen Return On Equity | 0.1 |
Most of Repligen's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Repligen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Repligen has a Return On Equity of 0.1016. This is 100.42% lower than that of the Healthcare sector and 100.28% lower than that of the Biotechnology industry. The return on equity for all Germany stocks is 132.77% lower than that of the firm.
Repligen Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Repligen's current stock value. Our valuation model uses many indicators to compare Repligen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Repligen competition to find correlations between indicators driving Repligen's intrinsic value. More Info.Repligen is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about 0.50 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Repligen is roughly 2.00 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Repligen's earnings, one of the primary drivers of an investment's value.About Repligen Financial Statements
Repligen stakeholders use historical fundamental indicators, such as Repligen's revenue or net income, to determine how well the company is positioned to perform in the future. Although Repligen investors may analyze each financial statement separately, they are all interrelated. For example, changes in Repligen's assets and liabilities are reflected in the revenues and expenses on Repligen's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Repligen. Please read more on our technical analysis and fundamental analysis pages.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. REPLIGEN CORP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 548 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Repligen Stock
When determining whether Repligen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Repligen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Repligen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Repligen Stock:Check out the analysis of Repligen Correlation against competitors. For more detail on how to invest in Repligen Stock please use our How to Invest in Repligen guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.